To detect GC outcomes, it was recently proposed to increase the amount of research on clinical biomarkers, such as epiregulin 43, the albumin-to-globulin ratio (AGR) and the lymphocyte-to-monocyte ratio (LMR) 44 in patients with GC. Here, ALB is linked to gastric cancer.